Related Experiment Videos
Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients
Christina I Fytili1, Euaggelia G Progia, Stelios A Panagoutsos
1Biochemical Department, G.H.N. Papanikolaou Thessaloniki, Greece.
Insights
Lipid abnormalities and lipoprotein metabolism differ between hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) patients with end-stage renal disease (ESRD). These changes may influence atherosclerotic vascular disease risk in dialyzed ESRD patients.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Clinical Chemistry
Background:
- Lipid abnormalities are key factors in vascular atherosclerotic lesion development in end-stage renal disease (ESRD) patients.
- Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerosis in ESRD.
- Understanding lipid profile variations in different renal replacement therapies is crucial for managing cardiovascular risk.
Purpose of the Study:
- To evaluate and compare lipid and apolipoprotein changes in hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) patients.
- To assess the impact of renal replacement modalities on lipoprotein metabolism and Lp(a) levels.
- To investigate the relationship between lipid profiles, albumin levels, and atherosclerotic risk in ESRD patients.
Main Methods:
- Serum levels of total cholesterol (TC), HDL-cholesterol (HDLc), LDL-cholesterol (LDLc), triglycerides (TG), apolipoproteins (A-I, A-II, B, E), Lp(a), and albumin were measured.
- 109 ESRD patients (46 HD, 63 CAPD) and 45 healthy controls with high lipids/TG were studied.
- Lipid profiles were analyzed in relation to dialysis modality and duration.
Main Results:
- Both HD and CAPD groups showed significantly higher TC, TG, LDL-C, Apo-B, and Apo-E levels compared to controls.
- HDL-C levels were significantly lower in both dialysis groups.
- Lp(a) levels remained stable in HD but increased significantly in CAPD patients, inversely correlated with albumin levels.
Conclusions:
- Renal replacement therapies (HD and CAPD) differentially affect lipoprotein metabolism in ESRD patients.
- Altered lipid profiles and Lp(a) changes in dialyzed patients may contribute to the high risk of atherosclerotic vascular disease.
- Monitoring lipid profiles and albumin is essential for risk stratification in ESRD patients undergoing dialysis.
Abstract:
Lipid abnormalities are important variables in the development of vascular atherosclerotic lesions in ESRD patients while Lp(a) represents an independent risk factor. In order to evaluate lipid changes in HD and CAPD patients, serum cholesterol (TC), HDLc, LDLc, TG, apolipoproteins (AI,AII,B,E), Lp(a), and albumin levels were estimated in 109 ESRD dialyzed patients, 46 in HD and 63 in CAPD (mean duration 50 +/- 40 and 25 +/- 19 months, respectively), and 45 volunteers with high serum levels of C and TG, without renal insufficiency. Both HD and PD group revealed statistically significantly higher levels than controls for TC, TG, LDL-C, Apo-B,-E, while HDL-C levels were significantly lower. Except for the lower serum albumin levels in both dialyzed groups after six months lower ApoAI levels and higher ApoB levels were observed in HD and PD patients respectively. Lp(a) levels remained unchanged in HD group, while a statistically significant increase appeared in PD patients that was negative correlated with the decreased serum albumin levels. These results indicate that renal replacement modalities result in a different effect in lipoprotein metabolism that may play an important role in atherosclerotic vascular disease of dialyzed ESRD patients.